QPS, a prominent global contract research organization, has introduced enhanced laboratory services at its Springfield, Missouri unit. This expansion complements the company’s existing bioanalysis, translational medicine, and peripheral blood mononuclear cell (PBMC) laboratories, extending its comprehensive services.
The newly expanded clinical trials unit now offers clinical trial sample analysis and leukopak cell therapy products. Additionally, the Springfield facility now provides expanded PBMC services, complementing those offered at the Miami, Florida location.
Housed within the existing clinical laboratory, the modern central laboratory for sample analysis employs advanced technologies for chemistry, urinalysis, serology, coagulation, and hematology testing. This capability enables real-time monitoring of subject safety during clinical trials.
QPS has established a specialized leukopak products collection and processing facility to meet the growing demand for blood products supporting cell therapy research. The company’s extensive database of potential study participants facilitates the identification of blood donors for leukopak products.
The enhanced PBMC services include a new PBMC processing lab in Springfield to address the unmet need for such services in the Midwest. This lab enables timely PBMC sample analysis, a critical aspect of vaccine trials.
Brendon Bourg, Vice President of Early Phase Clinical and Head of Administration at QPS Missouri indicated that these new facilities and services strengthen their comprehensive CRO capabilities and that clients can now access a full range of clinical research services at a single location.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
